相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard et al.
LANCET (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study
Irving Kaplan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
Anthony D'Amico et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
Rhonda L. Bitting et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research
Andrew L. Laccetti et al.
ONCOTARGETS AND THERAPY (2020)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
James W. Denham et al.
LANCET ONCOLOGY (2019)
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options
Martin G. Sanda et al.
JOURNAL OF UROLOGY (2018)
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study
Susan Slovin et al.
JAMA ONCOLOGY (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer
Zachary S. Zumsteg et al.
BJU INTERNATIONAL (2017)
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer Data From Patients in the Control Arm of the STAMPEDE Trial
Nicholas D. James et al.
JAMA ONCOLOGY (2016)
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Paul L. Nguyen et al.
EUROPEAN UROLOGY (2015)
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 1-and 2-Year Open-label Follow-up Results
Bertrand Tombal et al.
EUROPEAN UROLOGY (2015)
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902
Seth A. Rosenthal et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial
Almudena Zapatero et al.
LANCET ONCOLOGY (2015)
The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Population-Based Study
Chad G. Rusthoven et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
Bertrand Tombal et al.
LANCET ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413
Fabio L. Cury et al.
CANCER (2013)
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
Yangmin M. Ning et al.
CLINICAL CANCER RESEARCH (2013)
Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Andressa Ardiani et al.
CLINICAL CANCER RESEARCH (2013)
Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival
Jonathan D. Tward et al.
PRACTICAL RADIATION ONCOLOGY (2013)
Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis
Alberto Briganti et al.
EUROPEAN UROLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-term urinary adverse effects of pelvic radiotherapy
Sean P. Elliott et al.
WORLD JOURNAL OF UROLOGY (2011)
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Matthew R. Cooperberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Michel Bolla et al.
LANCET ONCOLOGY (2010)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610
Mack Roach et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Eric M. Horwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31
MV Pilepich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
分享论文
